DOCSLIB.ORG

Handbook 2015

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

2015 Handbook genesis 2015 60 years ago, British researchers co-discovered the structure of DNA. Today they continue to make world-changing discoveries. Unlock your global business potential with UK innovation. DNA (deoxyribonucleic acid) molecule gov.uk/ukti sponsors 3 Genesis 2015 Sponsors Contents Gold Sponsors Welcome 6 Keynote Speakers 7 Speaker Profiles 8 - 25 Programme 26 - 27 Floor Plan and Exhibitor List 28 - 29 The Source Lounge 32 Exhibitors 34 - 43 Silver Sponsors Corporate Patron Corporate Sponsors Bronze Sponsors Partners Supporters 60 years ago, British researchers co-discovered the structure of DNA. Today they continue to make world-changing discoveries. Unlock your global business potential with UK innovation. Media Partners DNA (deoxyribonucleic acid) molecule gov.uk/ukti Media Supporters Catalysing the power “Life sciences is the most of the golden triangle exciting and rewarding sector to invest in” Dr Eliot Forster, CEO, Immunocore, and Executive Chair, MedCity From the Francis Crick Institute and the Early-stage life sciences companies offer Cell Therapy Catapult to Imperial West and exciting opportunities for investors to make AstraZeneca’s Global R&D Centre, the life excellent returns and make a difference to sciences constellation of the London-Oxford- the health and well-being of thousands. Cambridge golden triangle is in a period of unprecedented ambition. Angels in MedCity runs regular free workshops for potential investors to understand the sector, Established by the Mayor of London with the identify strong propositions and connect with capital’s three academic health science centres, angel syndicates led by sector experts. MedCity is championing entrepreneurship and investment to build on the region’s global Angels in MedCity is a partnership between MedCity, London Business Angels and Angels4LifeSciences. reputation as a world-leading life sciences cluster. Find out how we can help you do business Find out more about opportunities for across the greater south east of England investors and emerging companies at medcityhq.com angelsinmedcity.org.uk MedCity_Adverts_Genesis_Conference_2015_AW.indd All Pages 05/11/2015 14:29 Catalysing the power “Life sciences is the most of the golden triangle exciting and rewarding sector to invest in” Dr Eliot Forster, CEO, Immunocore, and Executive Chair, MedCity From the Francis Crick Institute and the Early-stage life sciences companies offer Cell Therapy Catapult to Imperial West and exciting opportunities for investors to make AstraZeneca’s Global R&D Centre, the life excellent returns and make a difference to sciences constellation of the London-Oxford- the health and well-being of thousands. Cambridge golden triangle is in a period of unprecedented ambition. Angels in MedCity runs regular free workshops for potential investors to understand the sector, Established by the Mayor of London with the identify strong propositions and connect with capital’s three academic health science centres, angel syndicates led by sector experts. MedCity is championing entrepreneurship and investment to build on the region’s global Angels in MedCity is a partnership between MedCity, London Business Angels and Angels4LifeSciences. reputation as a world-leading life sciences cluster. Find out how we can help you do business Find out more about opportunities for across the greater south east of England investors and emerging companies at medcityhq.com angelsinmedcity.org.uk MedCity_Adverts_Genesis_Conference_2015_AW.indd All Pages 05/11/2015 14:29 6 welcome welcome Dear Genesis Participant, Welcome to our 15th Annual Genesis Conference The overarching theme of this year’s informatics elements of the sector. We conference is ‘Taking Bio-Innovation continue to have our partnering system to a Global Market’. Our programme for you and are delighted that the Life addresses this with content covering the Sciences Hub Wales is our new partner three main pillars for growth in the sector; for this. You can find partnering in the technology, finance and people. Fleming Room. The One Nucleus team and I know you Last year we brought you the first will make full use of the presentations, ever ‘Genesis Fringe’ – a range of great debate, networking and the exhibition events and activities taking place before hall to catch up with old friends and make and after Genesis that One Nucleus is some new ones, update yourselves on delighted to support and promote. We trends in the sector and create and scope got such great feedback from Genesis out new business opportunities. Please guests, who were able to maximise do not hesitate to talk with any one of the benefits of their trip, that we have the One Nucleus team. We are here to brought it back for 2015. I hope you have help you make the most of your time at experienced, or plan to experience a Genesis and ensure you leave us with Genesis Fringe event during your time in a spring in your step and light of heart London. Do check out page 29 for details. knowing that you have just had a hugely productive day! We are also continuing with the much appreciated (by us and guests) The One Nucleus membership continues collaboration with the SCRIP team on to grow and we remain the largest Genesis. We have worked incredibly membership organisation for the sector closely together on key elements of in Europe (by some distance, with over the day, evolving it to enhance the 470 organisations as members). The knowledge-sharing opportunities for majority of our members are based in you. The insights gained over the day Cambridge and London with many of will fuel the much anticipated SCRIP-One them here today. Nucleus Plenary Debate providing the panellists and delegates with the chance Genesis continues to be a truly to share their suggestions to enhance international networking exhibition that success at individual, company and sector we intentionally evolve year on year. wide level. New for 2015 we have an intentionally reformatted Exhibition Hall affording all Finally and very importantly I would stands greater visibility, more specific like to extend a big ‘thank you’ to all our Source Hubs (after the success of our Sponsors, supporters and collaborators inaugural Source Lounge last year) and for helping to make Genesis happen. 1-2-1 clinic options on (i) Get Ready for JP Morgan 2016 (ii) Outsourcing R&D I wish everyone an excellent event and and (iii) Preparing for Start-Up and High thank you for taking part. Growth. We have updated the core programme to include an additional Plenary Panel which increases the programme content and dynamic further as does the addition of the Farr Institute stream which brings in the health keynote speakers 7 George Freeman MP Minister for Life Sciences George was elected to Parliament in 2010 after a 15 year career across the life sciences sector, in particular working with hospitals, clinical researchers, patient groups, and biomedical research companies to pioneer novel healthcare innovations. Following his election to Parliament in 2010, George served as PPS to the Minister of State for Climate Change. He was appointed Government Adviser on Life Sciences in July 2011, working closely with the Department of Health and coordinating the Government’s Life Science and Innovation, Health and Wealth Strategies (2011), and the Agri-Tech Industrial Strategy (2013). Following that, he was appointed to the post of Prime Minister’s UK Trade Envoy. On July 15 2014, George was appointed as Minister for Life Sciences, a Parliamentary Under-Secretary of State at the Department of Health and Department of Business, Innovation and Skills. His mission is to make the UK the best place in the world to discover and develop 21st Century healthcare innovations. Richard Mason Head of Johnson & Johnson Innovation, London Richard joins Johnson & Johnson Innovation from XO1-Limited where he served as CEO before it was acquired by Janssen earlier this year. Richard is a physician by training and has had a number of senior roles in innovative biotechnology companies. Richard specializes in transforming companies through collaborations and deal-making, including multiple acquisitions. Richard earned his MBA from The Judge Business School University of Cambridge. Mike Ward Chief Content Officer, SCRIP Intelligence and Datamonitor Mike has been writing, analysing and commenting on the life sciences industry for the past 30 years. He has focused on business models, R&D strategies and how to finance innovation, and is often called upon by the industry’s key stakeholders to provide thought leadership. In 2010 he was named European Mediscience Commentator of the Year. 8 speaker profiles Eva-Lotta Allan CBO and Board Director, Immunocore Eva-Lotta Allan has over two decades of business development experience from the biotechnology and life science industry of private and public companies. She joined Immunocore as Chief Business Officer and Board Director in May 2013. Since then Immunocore has established four pharmaceutical discovery partnerships. Eva-Lotta was previously at Ablynx, serving as CBO for almost seven years and held roles in biotech companies including Senior Director of Business Development and Site Operations (Europe) at Vertex Pharmaceuticals. Davidson Ateh CEO, BioMoti Davidson Ateh is a health entrepreneur. He is a past recipient of the prestigious Royal Society of Edinburgh/BBSRC Enterprise Fellowship and has a successful track record of financing disruptive ideas and progressing new technology. He is the CEO of BioMoti that is seeking to transform the treatment of cancer using its precision immunotherapeutic nanomedine platform: Oncojans™. BioMoti candidates have the potential to be ground-breaking cancer therapies for patients in need. Graham Ball Professor of Bioinformatics, Nottingham Trent University and CSO of CompanDX and CompanDX(Wuhan) Prof Graham Ball is Professor of Bioinformatics at Nottingham Trent University and CSO of CompanDX Ltd and CompanDX(Wuhan) Ltd. He is Associate Director the John Van Geest Cancer Research Centre and biostatistics lead on three clinical projects. He has been involved in the development and validation of biomarker discovery algorithms using Artificial Neural Networks for the last 20 years.
Recommended publications
  • Initiation IBT

    Initiation IBT

    6 July 2021 Pharmaceuticals & Biotechnology INTL. BIOTECHNOLOGY TRUST Investing in a broad spectrum of the drug industry IBT was established in 1994 to provide institutional and retail investors with the opportunity to participate in global biotechnology and life science companies, from early-stage development via venture capital (SV Health Investors funds) through to global, multinational biotechnology companies. The main aim of the trust is to Source: Refinitiv generate capital growth, while minimising risk, through a diversified portfolio and with an experienced investment management team. Over the last five years, IBT’s Market data NAV has increased 62%, while the share price has increased 92% over the same EPIC/TKR IBT period – the superior returns generally reflected by a share price premium. Price (p) 755 12m high (p) 862 12m low (p) 653 ► Strategy: IBT’s investment objective is to achieve long-term capital growth by Shares (m) 41.38 investing in biotechnology companies that address unmet medical needs. The Mkt cap (£m) 312 trust offers a diversified portfolio of listed and private companies on a global NAV (£m) 293 basis, although the vast majority of investments are currently in the US. NAV/share (p) 710 Premium/discount to NAV 6% ► Market updates: With 89% of the investment portfolio currently in listed Country of listing UK companies, the NAV changes on a daily basis. IBT has a daily update on its Market Main website, produces informative monthly factsheets (https://ibtplc.com/investor# factsheets), and shows the full portfolio of US listed investments quarterly in Description filings with the SEC (https://ibtplc.com/portfolio).
  • COVID-19 Response Interim Report

    COVID-19 Response Interim Report

    JUNE 2021 COVID-19 response interim report Interim Report (January 2020 to March 2021) Medical Research Council Evaluation and Analysis Team I Foreword The intent of this report is to document the main activities undertaken by Medical Research Council (MRC), part of UK Research and Innovation (UKRI), and its community of researchers in response to the SARS-CoV-2 pandemic and to recognise the impacts and insights arising from these activities. As the response and outcomes will continue past 2021, this is an interim report covering January 2020 to March 2021. It is proposed that a final form of this report is produced in 2022. The report is a collection of eight summaries of separate components of the MRC-led aspects of the UKRI COVID-19 response and their impact rather than a connected narrative of events. Highlighted blue and bold text provide links to more detailed descriptions either within the document and the Annexes or external webpages. Methods and acknowledgements The information in this paper has been gathered live throughout 2020. Funding activity data was collated from various off-line call processes by Matt Coles. Activity, outcomes, and impact information from the research community was primarily self-reported in project and Institute, Unit and Centre surveys and Researchfish®. Interviews were undertaken with MRC staff in May and October 2020 and in January 2021. The data was gathered, and the report composed by Emily Gale, Ian Viney, Buddhini Samarasinghe, and James Carter. Additional analysis was provided by the members of the Evaluation and Analysis Team: Joe Murphy and Dominic Hedges.
  • Investment Manager Review NAV and Share Price

    Investment Manager Review NAV and Share Price

    FACTSHEET — SEPTEMBER 2020 ibtplc.com Investment Manager Review In September 2020, the Trust’s NAV per share returned 7.5%* (GBP) while the NASDAQ Biotechnology Index (NBI) returned 5.3%* (GBP). The FTSE All-Share Index returned -1.7%* (GBP) and the S&P 500 Index returned -0.9%* (GBP). IBT’s share price returned 9.0%* (GBP). Key attributes of the Trust The main positive contributors to NAV in the month were Immunomedics, Myokardia and Horizon Driven by strong fundamentals of the Biotech Therapeutics. The Trust’s NAV benefited following the announcement that Gilead, a top-10 holding, intended sector. to acquire Immunomedics for USD 21bn, representing a 108% premium to the previous day’s closing price. Access to a broad spectrum of quoted and Myokardia’s share price increased following the release of positive phase 3 EXPLORER-HCM clinical trial unquoted investments. results for Mavacamten, a treatment for Obstructive Hypertrophic Cardiomyopathy. Horizon Therapeutics’ share price continues to perform well, driven by strong sales data from their lead asset, Tepezza. Provides investors exposure to both growth and a competitive yield. The main detractors from the NAV in the month were Neurocrine, Halozyme and Regeneron. Neurocrine’s Bottom up stock selection with diversification share price performed poorly during the month. There was no specific event that triggered this performance. overlay. However, Neurocrine’s third quarter sales have historically been weak which may have affected investor Medically and financially experienced Fund sentiment. Halozyme’s share price was negatively affected by the news that Johnson & Johnson had entered Managers with access to specialists at SV into arbitration with Genmab over royalty payment from the injection form of Darzalex.